Clinical Trial Update: Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update on a cysteinyl leukotriene antagonist aiming to inhibit atherosclerosis after endovascular treatment in peripheral arterial disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis of Artery
• Lower Limb Ischemia
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Drugs mentioned

• Cysteinyl leukotriene antagonist

Snippet

Sponsor: Jagiellonian University | Conditions: Peripheral Arterial Disease, Peripheral Vascular Diseases | Phase 3 | Status: UNKNOWN